News

Anti-MEK-PI3K Drug Combination Reduces Solid Tumor Lesions

Publish date: April 11, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

"I hope I am wrong," he said.

Genentech sponsored the study. Dr. Bendell said she had no relevant financial disclosures. Dr. Der disclosed relationships with GlaxoSmithKline, Millipore, Bristol-Myers Squibb, and Sanofi-Aventis.

Pages

Recommended Reading

SDEF: Consider Potential Risks of Newly Approved Therapeutics
MDedge Dermatology
SDEF: New Melanoma Treatments Show Improved Survival
MDedge Dermatology
SDEF: Abtropfung, Hochsteigerung Theories of Nevus Evolution Questioned
MDedge Dermatology
SDEF: Capecitabine May Protect Against Skin Cancers After Transplant
MDedge Dermatology
SDEF: FDA Approval Expected this Month for Ipilimumab
MDedge Dermatology
Preop Ultrasound Unreliable in Melanoma Staging
MDedge Dermatology
Ipilimumab Approval Marks New Era in Melanoma Treatment
MDedge Dermatology
Vismodegib Effectively Combats BCC in Phase II Study
MDedge Dermatology
New Study Yields Mixed Results for SN Biopsy in Melanoma
MDedge Dermatology
Surgical Margins for Melanoma: Simple Excision? [editorial]
MDedge Dermatology